1.51
price up icon4.14%   0.06
after-market アフターアワーズ: 1.51
loading
前日終値:
$1.45
開ける:
$1.51
24時間の取引高:
430.82K
Relative Volume:
2.10
時価総額:
$47.11M
収益:
$81,000
当期純損益:
$-41.04M
株価収益率:
-1.1466
EPS:
-1.3169
ネットキャッシュフロー:
$-30.69M
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
+16.15%
6か月 パフォーマンス:
-5.03%
1年 パフォーマンス:
+20.80%
1日の値動き範囲:
Value
$1.47
$1.555
1週間の範囲:
Value
$1.3712
$1.555
52週間の値動き範囲:
Value
$1.06
$2.41

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name
名前
Actinium Pharmaceuticals Inc
Name
セクター
Healthcare (1123)
Name
電話
646-767-3870
Name
住所
275 Madison Avenue, 7th Floor, New York, NY
Name
職員
25
Name
Twitter
@actiniumpharma
Name
次回の収益日
2025-11-24
Name
最新のSEC提出書
Name
ATNM's Discussions on Twitter

ATNM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ATNM
Actinium Pharmaceuticals Inc
1.51 45.23M 81,000 -41.04M -30.69M -1.3169
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-07 ダウングレード B. Riley Securities Buy → Neutral
2024-05-14 開始されました Stephens Overweight
2023-09-06 開始されました HSBC Securities Buy
2023-02-21 ダウングレード William Blair Outperform → Mkt Perform
2022-09-08 開始されました Cantor Fitzgerald Overweight
2022-08-25 開始されました B. Riley Securities Buy
2020-11-05 開始されました Alliance Global Partners Buy
2017-12-06 開始されました B. Riley FBR, Inc. Buy
2017-10-23 再開されました ROTH Capital Buy
2017-09-14 開始されました Maxim Group Buy
2016-08-25 開始されました ROTH Capital Buy
2016-02-29 開始されました H.C. Wainwright Buy
2015-10-15 開始されました FBR Capital Outperform
2014-10-01 開始されました MLV & Co Buy
2014-07-22 開始されました Canaccord Genuity Buy
すべてを表示

Actinium Pharmaceuticals Inc (ATNM) 最新ニュース

pulisher
Dec 12, 2025

Actinium Pharmaceuticals stock rises after promising breast cancer therapy data - Investing.com

Dec 12, 2025
pulisher
Dec 12, 2025

Why Is Actinium Pharmaceuticals Stock Rising Today? - Menafn

Dec 12, 2025
pulisher
Dec 12, 2025

Why is Actinium Pharmaceuticals stock rising today? - MSN

Dec 12, 2025
pulisher
Dec 12, 2025

Actinium (ATNM) Reveals Promising Preclinical Data for Novel Can - GuruFocus

Dec 12, 2025
pulisher
Dec 12, 2025

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire

Dec 12, 2025
pulisher
Dec 11, 2025

Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia - openPR.com

Dec 11, 2025
pulisher
Dec 11, 2025

Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why - Defense World

Dec 11, 2025
pulisher
Dec 10, 2025

Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins - openPR.com

Dec 10, 2025
pulisher
Dec 10, 2025

Actinium Pharmaceuticals: Clinical Milestone and Promising Data Fuel Oncology Pipeline - AD HOC NEWS

Dec 10, 2025
pulisher
Dec 09, 2025

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances - openPR.com

Dec 09, 2025
pulisher
Dec 09, 2025

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer - marketscreener.com

Dec 09, 2025
pulisher
Dec 08, 2025

ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa - openPR.com

Dec 08, 2025
pulisher
Dec 08, 2025

Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa - openPR.com

Dec 08, 2025
pulisher
Dec 05, 2025

Can Actinium Pharmaceuticals Inc. (7AY1) stock double in coming yearsJuly 2025 Opening Moves & Safe Entry Point Alerts - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Will Actinium Pharmaceuticals Inc. (Delaware) stock gain from lower interest ratesJuly 2025 Highlights & Risk Controlled Stock Alerts - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Why analysts recommend Actinium Pharmaceuticals Inc. (Delaware) stock2025 Earnings Surprises & Daily Entry Point Trade Alerts - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international markets2025 Short Interest & Real-Time Chart Pattern Alerts - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Will Actinium Pharmaceuticals Inc. (Delaware) stock beat Nasdaq index returnsChart Signals & Consistent Profit Alerts - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Why hedge funds are buying Actinium Pharmaceuticals Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

Why Actinium Pharmaceuticals Inc. stock is a value investor pick2025 Market WrapUp & Expert Approved Trade Ideas - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily

Dec 02, 2025
pulisher
Dec 02, 2025

Will Actinium Pharmaceuticals Inc. stock benefit from green energy trendsJobs Report & Daily Entry Point Alerts - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

How Actinium Pharmaceuticals Inc. (7AY1) stock valuation compares with sectorQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

How cyclical is Actinium Pharmaceuticals Inc. (7AY1) stock compared to rivalsJuly 2025 Volume & Smart Investment Allocation Insights - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

Actinium’s ATNM-400 shows efficacy in resistant breast cancers By Investing.com - Investing.com Australia

Dec 01, 2025
pulisher
Dec 01, 2025

Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Da - GuruFocus

Dec 01, 2025
pulisher
Dec 01, 2025

Actinium's ATNM-400 shows strong efficacy in TNBC, beats therapy resistance at SABCS - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

Actinium’s ATNM-400 shows efficacy in resistant breast cancers - Investing.com

Dec 01, 2025
pulisher
Dec 01, 2025

Actinium Pharma details ATNM-400 in resistant breast cancer | ATNM Stock News - Stock Titan

Dec 01, 2025
pulisher
Dec 01, 2025

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire

Dec 01, 2025
pulisher
Nov 30, 2025

Securities Fraud Class Action Filed Against Actinium Pharmaceutic - The National Law Review

Nov 30, 2025
pulisher
Nov 30, 2025

Decliners Report: Will Actinium Pharmaceuticals Inc. stock outperform value stocksCPI Data & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ

Nov 30, 2025
pulisher
Nov 29, 2025

Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Market Overview & Precise Entry and Exit Recommendations - BỘ NỘI VỤ

Nov 29, 2025
pulisher
Nov 27, 2025

Bull Bear: Can Actinium Pharmaceuticals Inc. stock continue upward trend2025 Retail Activity & AI Enhanced Trading Alerts - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

ROSEN, A LONGSTANDING FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATNM - 28/22 News

Nov 27, 2025
pulisher
Nov 27, 2025

Actinium Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Australia

Nov 27, 2025
pulisher
Nov 26, 2025

Actinium Pharmaceuticals elects directors and approves proposals at annual meeting By Investing.com - Investing.com South Africa

Nov 26, 2025
pulisher
Nov 26, 2025

Actinium Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Nov 26, 2025
pulisher
Nov 26, 2025

Actinium ATNM holders back board, 3-year say-on-pay cycle - Stock Titan

Nov 26, 2025
pulisher
Nov 21, 2025

Why institutional investors increase stakes in Actinium Pharmaceuticals Inc. (7AY1) stock - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Is Actinium Pharmaceuticals Inc. (Delaware) stock a fit for income portfoliosJuly 2025 Catalysts & Advanced Technical Signal Analysis - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

How Actinium Pharmaceuticals Inc. stock benefits from global expansionMarket Trend Report & Reliable Entry Point Alerts - newser.com

Nov 20, 2025

Actinium Pharmaceuticals Inc (ATNM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
大文字化:     |  ボリューム (24 時間):